EMA recommends non-renewal of authorisation of Duchenne muscular dystrophy medicine Translarna

View source ↗

Summary

The EMA recommends non-renewal of the marketing authorisation for Translarna (ataluren) for Duchenne muscular dystrophy in the EU after reviewing data and exper…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Translarna (ataluren)

Snippet

Opinion follows review of additional data and advice from group of experts.